Stemina Biomarker Discovery was established in November 2006 and co-founded by Elizabeth Donley, JD, MBA, MS and Gabriela Cezar, DVM, PhD. Stemina’s technology arose from the pioneering work of Dr. Cezar at the University of Wisconsin-Madison. Stemina opened its doors in its current location in Madison, Wisconsin on November 1, 2007.
The company’s first commercial product, devTOX Discovery, was launched in March 2009 at the Society of Toxicology’s Annual Meeting. This screening service uses human embryonic stem cells or induced pluripotent stem cells to screen drug candidates, chemicals, consumer products, and cosmetics for their potential effect on the developing human embryo.
Additional drug screening programs, including devTOX quickPredict and Cardio quickPredict, followed and continue to be refined and developed. All continue the idea of bringing stem cell biology and metabolomics together for biomarker discovery.
The Stemina team has grown, adding skilled staff to the toxicology company and the neurological disorders division, which was launched in 2014. Stemina and NeuroPointDX continue to expand with new efforts, such as adding endpoints to our cardiotoxicity assay, Cardio quickPredict, and conducting research on potential treatments to help children with specific metabolic subtypes of autism spectrum disorder.